Steps to building a more patient-centric industry
Pharma Phorum
DECEMBER 1, 2022
Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials.
Sat.Nov 26, 2022 - Fri.Dec 02, 2022
91 
FDA approves first microbiota-based treatment
Bio Pharma Dive
DECEMBER 1, 2022
The regulatory OK, a milestone for microbiome-based drug research, is for a medicine from Ferring Pharma that treats a recurrent type of gut infection
Join 15,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Trending Sources
NHS expedites rollout of Bayer’s darolutamide for prostate cancer
Pharmaceutical Technology
NOVEMBER 29, 2022
The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts.
Botanical Solution Inc. (BSI) & Croda Pharma Partnership Agreement to Accelerate Production for GMP QS-21
Pharma Mirror
DECEMBER 1, 2022
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications. Botanical Solution Inc.
2022 Research: The Rapid Rise of Ocean Freight Visibility
Advertiser: FourKites
Download this a benchmark study from FourKites and The Journal of Commerce exploring how international shippers’ usage of global supply chain visibility technology has evolved since the onset of global disruptions caused by COVID-19.
Get Set up for Success in the Account Incubator Program
Intouch Solutions
DECEMBER 1, 2022
Finding an agency job after graduating college can feel overwhelming, but it doesn’t have to. Jumpstart your career at EVERSANA INTOUCH and be set up for success as part of our Account Incubator program where you can dip your toes into an Account Services role!
What to make of Eisai and Biogen’s latest Alzheimer’s drug data
Bio Pharma Dive
NOVEMBER 29, 2022
At a medical conference, the companies detailed clinical trial results that could help support approval of their drug, lecanemab. However, some doctors aren’t yet convinced the medicine’s risks are worth its potential benefits
Sign up to get articles personalized to your interests!
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
More Trending
Role of data in shaping the future of Healthcare AI
Pharma Mirror
NOVEMBER 29, 2022
As AI technology advances, it is quickly finding its way into the world of healthcare. The rise of machine learning and chatbots in healthcare is moving away from the traditionally doctor-centric model and towards a more patient-centric and automated process built on trust and data.
The European Commission and WHO extend their strategic cooperation to deliver better health for all
The Pharma Data
DECEMBER 2, 2022
The European Commission and WHO extend their strategic cooperation to deliver better health for all.
Sana reshuffles drug pipeline, becoming latest biotech to cut staff
Bio Pharma Dive
NOVEMBER 30, 2022
The richly funded drugmaker will cut 15% of its workforce, or about 75 employees, as well as stop work on one of its preclinical research programs
Expanding ketamine’s horizons to treat rare neurological disorders
Pharmaceutical Technology
NOVEMBER 29, 2022
For several decades, researchers have been investigating the role of ketamine in treating depression. Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome.
An Innovative & Creative Problem Solver Approach to Selling in the Medical Device Space
Speaker: Steve Goldstein, Sales Leader
Currently in sales or involved in a business that depends on strong sales results? Join Steve Goldstein, Sales Success Coach, Motivational Speaker and Medical Device Sales Leader from Gold Selling LLC. You will absorb critical strategies to become a trusted partner in greater sales success.
Touchlight receives funding to develeop DNA vaccine platform
Pharma Times
NOVEMBER 29, 2022
Bill & Melinda Gates Foundation grant will boost potential of nanoparticle-formulated doggybone DNA
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022
The Pharma Data
NOVEMBER 28, 2022
AMGEN TO WEBCAST INVESTOR CALL AT WCIRDC 2022. Amgen (NASDAQ: AMGN) will host a webcast call for the investment community in conjunction with the World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) at 8:00 a.m. ET on Monday, Dec. 5, 2022. David M. Reese, M.D.,
Rigel wins US approval of rival drug to Servier leukemia treatment
Bio Pharma Dive
DECEMBER 2, 2022
The approval gives Rigel, a biotech that’s been around since the mid-1990s, its second marketed medicine and a competitor to Servier’s Tibsovo
US FDA approves Ferring’s Rebyota for Clostridioides difficile infection
Pharmaceutical Technology
DECEMBER 1, 2022
The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above.
Mandatory COVID Vaccination Policy Template
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Eisai and Biogen present promising lecanemab study results
Pharma Times
NOVEMBER 30, 2022
Phase 3 research shows that Alzheimer’s disease treatment meets primary and secondary endpoints
WHO recommends a new name for monkeypox disease
The Pharma Data
NOVEMBER 28, 2022
WHO recommends a new name for monkeypox disease. Following a series of consultations with global experts, WHO will begin using a new preferred term “mpox” as a synonym for monkeypox. Both names will be used simultaneously for one year while “monkeypox” is phased out.
Pfizer, Roivant set up new company around inflammation drug
Bio Pharma Dive
DECEMBER 1, 2022
The drug is currently in mid-stage testing as a treatment for ulcerative colitis. If it continues to advance, it could be the first approved therapy aimed at a protein known as TL1A, a target multiple other companies are pursuing
The “Medical Bypass”: new drugs to strike obesity
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries.
Healthcare leaders warn about unsustainable pressure on mental health services
Pharma Times
DECEMBER 2, 2022
Patients and service users routinely struggle to access mental healthcare across the NHS
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker
Fierce Pharma
DECEMBER 2, 2022
With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner. Fri, 12/02/2022 - 09:51
FDA lifts pause on Beam plans to test base editing cancer therapy
Bio Pharma Dive
DECEMBER 2, 2022
The FDA’s decision is a step forward for a type of drugmaking known as “multiplex editing,” which involves editing several genes simultaneously
C4XD and AstraZeneca enter $402m deal to develop respiratory disease therapy
Pharmaceutical Technology
NOVEMBER 28, 2022
C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments.
Immutep in clinical trail collaboration with Merck KGaA and Pfizer
Pharma Times
NOVEMBER 29, 2022
Research will focus on eftilagimod alpha and avelumab for the treatment of urothelial cancer
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy
Fierce Pharma
NOVEMBER 28, 2022
Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy. ntaylor. Mon, 11/28/2022 - 10:11
Spectrum to lay off R&D staff after FDA drug rejection
Bio Pharma Dive
NOVEMBER 28, 2022
The company will cut its R&D workforce by 75% and discontinue development of its experimental lung cancer drug poziotinib
Current pipeline developments could bring new hope for patients with PPMS
Pharmaceutical Technology
NOVEMBER 30, 2022
Multiple sclerosis (MS) is an autoimmune disease causing chronic inflammation and demyelination of the nerves, affecting around 2.5 million people worldwide.
C4XD signs NRF2 Activator deal with AstraZeneca
Pharma Times
NOVEMBER 28, 2022
C4XD will receive milestone payments worth up to $16m ahead of the first clinical trial
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2
Fierce Pharma
DECEMBER 1, 2022
With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. kdunleavy. Thu, 12/01/2022 - 10:14
Gene editing startup iECURE returns to investors for fresh funding
Bio Pharma Dive
NOVEMBER 30, 2022
The company, which draws on research by Jim Wilson’s lab at UPenn, says the $65 million it raised will support the start of human testing of its lead drug through to initial clinical data
The “Medical Bypass”: new drugs to strike obesity
Pharmaceutical Technology
NOVEMBER 30, 2022
In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries.
Respiratory vaccination candidate tested in German hospitals
Pharma Times
DECEMBER 1, 2022
Novel tuberculosis vaccine tested in a large phase 3 trial against severe respiratory infection disease
Second Circuit Decision A Reminder that Alleged FDCA violations don’t always equal FCA violations
The FDA Law Blog
NOVEMBER 30, 2022
By JP Ellison & Holly N.
Mainstreaming cell and gene therapy – Realizing its potential
Bio Pharma Dive
NOVEMBER 28, 2022
The challenges biopharma companies face in running clinical trials and tips on how to surmount those obstacles
How to cut drug supply costs with seamless forecasting and IRT systems
Pharmaceutical Technology
DECEMBER 2, 2022
An accurate drug supply forecast is essential for a successful clinical trial. Without it, sponsors risk a shortage of investigative medicinal product (IMP) for patients, resulting in major trial delays.
Let's personalize your content